Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ptc Therapeutics (PTCT) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Ptc Therapeutics (PTCT) over the last 14 years, with Q3 2025 value amounting to 1.43%.

  • Ptc Therapeutics' EBITDA Margin rose 291300.0% to 1.43% in Q3 2025 from the same period last year, while for Sep 2025 it was 43.61%, marking a year-over-year increase of 624300.0%. This contributed to the annual value of 37.5% for FY2024, which is 93600.0% up from last year.
  • Ptc Therapeutics' EBITDA Margin amounted to 1.43% in Q3 2025, which was up 291300.0% from 19.54% recorded in Q2 2025.
  • In the past 5 years, Ptc Therapeutics' EBITDA Margin ranged from a high of 82.5% in Q1 2025 and a low of 119.67% during Q4 2022
  • Over the past 5 years, Ptc Therapeutics' median EBITDA Margin value was 54.58% (recorded in 2022), while the average stood at 45.65%.
  • Its EBITDA Margin has fluctuated over the past 5 years, first soared by 1644900bps in 2021, then crashed by -780700bps in 2024.
  • Ptc Therapeutics' EBITDA Margin (Quarter) stood at 51.28% in 2021, then tumbled by -133bps to 119.67% in 2022, then surged by 102bps to 1.9% in 2023, then crashed by -4119bps to 76.18% in 2024, then skyrocketed by 102bps to 1.43% in 2025.
  • Its EBITDA Margin was 1.43% in Q3 2025, compared to 19.54% in Q2 2025 and 82.5% in Q1 2025.